Summary
Currently the only treatmen for wet AMD is intravitreal razimomab. This requires monthly injections in a facility. There is also the possibilty of hemorrhage or infection.
Analysis
There is an expanding market with the aging population and recognition by ophthalmologists of early pathology especially with
new imaging techniques. There is also an increasing awareness
of the disease.
This author consults with leading institutions through GLG
Analyses are solely the work of the authors and have not been edited or endorsed by GLG.
